The Long-Term Outcome of Treatment for Graves' Hyperthyroidism
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: The treatment efficacy of antithyroid drug (ATD) therapy, radioactive iodine ( 131 I), or surgery for Graves' hyperthyroidism is well described. However, there are a few reports on the long-term total outcome of each treatment modality regarding how many require levothyroxine supplementation, the need of thyroid ablation, or the individual patient's estimation of their recovery. Methods: We conducted a pragmatic trial to determine the effectiveness and adverse outcome in a patient cohort newly diagnosed with Graves' hyperthyroidism between 2003 and 2005 ( n = 2430). The patients were invited to participate in a longitudinal study spanning 8 ± 0.9 years (mean ± standard deviation) after diagnosis. We were able to follow 1186 (60%) patients who had been treated with ATD, 131 I, or surgery. We determined the mode of treatment, remission rate, recurrence, quality of life, demographic data, comorbidities, and lifestyle factors through questionnaires and a review of the individual's medical history records. Results: At follow-up, the remission rate after first-line treatment choice with ATD was 45.3% (351/774), with 131 I therapy 81.5% (324/264), and with surgery 96.3% (52/54). Among those patients who had a second course of ATD, 29.4% achieved remission (vs. the 45.3% after the first course of ATD). The total number of patients who had undergone ablative treatment was 64.3% (763/1186), of whom 23% (278/1186) had received surgery, 43% (505/1186) had received 131 I therapy, including 2% (20/1186) who had received both surgery and 131 I. Patients who received ATD as first-line treatment and possibly additional ATD had 49.7% risk (385/774) of having undergone ablative treatment at follow-up. Levothyroxine replacement was needed in 23% (81/351) of the initially ATD treated in remission, in 77.3% (204/264) of the 131 I treated, and in 96.2% (50/52) of the surgically treated patients. Taken together after 6–10 years, and all treatment considered, normal thyroid hormone status without thyroxine supplementation was only achieved in 35.7% (423/1186) of all patients and in only 40.3% of those initially treated with ATD. The proportion of patients that did not feel fully recovered at follow-up was 25.3%. Conclusion: A patient selecting ATD therapy as the initial approach in the treatment of Graves' hyperthyroidism should be informed that they have only a 50.3% chance of ultimately avoiding ablative treatment and only a 40% chance of eventually being euthyroid without thyroid medication. Surprisingly, 1 in 4 patients did not feel fully recovered after 6–10 years. The treatment for Graves' hyperthyroidism, thus, has unexpected long-term consequences for many patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715 · cited 1×
“There are a few randomized trials of treatment of GD and, in particular, of the long-term effectiveness of the therapies (5,26,37,40,41).”
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521 · cited 12×
“However, the presence of TAO may contribute, as this condition significantly increases the risk for inability to work (4,5).”
InfluentialSelf-citationLaurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428 · cited 1×
“A second reason is most likely that in premenopausal women with an explicit wish to become pregnant we prefer thyroid surgery and avoid ATD and 131 I due to possible adverse effects on the fetus and the post-treatment rise in TRAb levels after 131 I therapy, respectively (26,49,50).”
Self-citationCancer Mortality Following Treatment for Adult Hyperthyroidism
Ron, E. (1998) · JAMA · doi:10.1001/jama.280.4.347 · Cited by 377
Franklyn, J. A., & Boelaert, K. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60782-4 · Cited by 262
Träisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0747 · Cited by 262
Self-citationIncidence of hyperthyroidism in Sweden
Abraham-Nordling, M., Byström, K., Törring, O., Lantz, M., Berg, G., Calissendorff, J., Nyström, H. F., Jansson, S., Jörneskog, G., Karlsson, F. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0548 · Cited by 251 · cited 1×
“In 2003–2005, all patients with newly diagnosed Graves’ hyperthyroidism or toxic nodular goiter (TNG) ( n = 2916) were registered in 7 cities in Sweden involving 13 endocrine clinics that covered a referral population corresponding to 40% of the Swedish population (1).”
Self-citation
Cited by
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Lee, S. Y., & Pearce, E. N. (2023) · JAMA · doi:10.1001/jama.2023.19052 · Cited by 295
Thyroid disease: Long-term management of hyperthyroidism and hypothyroidism
Hughes, K., & Eastman, C. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-09-20-5653 · Cited by 48
Skov, J., Calissendorff, J., Eriksson, D., Magnusson, P., Kämpe, O., Bensing, S., & Kuja-Halkola, R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa956 · Cited by 25
Self-citationPetit, P., Chamot, S., Al-Salameh, A., Cancé, C., Desailloud, R., & Bonneterre, V. (2024) · Environmental Research · doi:10.1016/j.envres.2024.118458 · Cited by 8
Metadata
- Authors
- Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham-Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., Filipsson Nyström, H., & Wallin, G.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2019-11-01
- Volume
- 29
- Issue
- 11
- Pages
- 1545-1557
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2972065880
- Cited by
- 102
- References
- 22
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. https://app.cochat.ai/papers/10.1089/thy.2019.0085
- The paper
- Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham-Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., Filipsson Nyström, H., & Wallin, G. (2019). The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Thyroid. https://doi.org/10.1089/thy.2019.0085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.